We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Abbott Selling Developed Market Generics Portfolio

By HospiMedica International staff writers
Posted on 29 Jul 2014
Print article
Abbott Laboratories (Abbot Park, IL, USA) has sold its developed market generic drugs business to Mylan (Canonsburg, PA, USA) in a deal worth USD 5.3 billion.

The sale to Mylan will be in the form of an equity ownership of a newly formed entity, to be named Mylan NV, in which Abbott will have a stake of 21%. The new entity will be based in the Netherlands to achieve tax savings. Mylan NV will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, which includes Europe, Japan, Canada, Australia, and New Zealand, as well as manufacturing facilities in France and Japan. The transaction will diversify Mylan's business and strengthen its commercial platform outside the US (the US sector is not included).

The assets, which are being acquired on a debt-free basis, include a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas—central nervous system/pain, cardio/metabolic, gastrointestinal, anti-infective/respiratory, and women's and men's health—and also includes several patent protected, novel, and hard-to-manufacture products with continued growth potential.

Abbott will retain its branded generics pharmaceuticals business and products in emerging markets, where demographics and growing healthcare systems are combining to create an increased rate of patient access to healthcare, and where the majority of healthcare products are paid for directly by the consumer. Abbott will also retain manufacturing facilities in emerging markets as well as those situated in the Netherlands, Germany, and Canada.

“This transaction provides Abbott with additional strategic flexibility as we continue to actively manage and shape our portfolio, reflecting our commitment to long-term, durable growth,” said Miles D. White, chairman and CEO of Abbott. “Our branded generics pharmaceuticals business will focus on emerging markets, where demographic changes and increasing access to healthcare are expected to drive sustainable growth.”

“We believe Mylan is uniquely positioned to realize improved financial performance and profitability from these assets by leveraging our integrated, efficient operating platform, more effectively distributing the portfolio across channels, and maintaining a greater strategic focus on key products,” said Heather Bresch, CEO of Mylan. “We have experience successfully integrating large, complex transactions such as this one, and we are confident in our ability to deliver the value inherent from this combination.”

Abbott does not expect to be a long-term shareholder in Mylan, and ultimately plans to redeploy the proceeds from the transaction to new opportunities in the devices and diagnostics sectors, with an emphasis on the diabetes, eye care, and vascular markets.

Related Links:

Abbott Laboratories
Mylan


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Surgial Headlight
MedLED Chrome

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.